Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy

Annals of Surgical Oncology

Volumn 17, Issue 1, 2010, Pages 247-253

  Jung, So Youn ^a   Kim, Seok Ki ^a   Nam, Byung Ho ^a   Min, Sun Young ^a   Lee, Seung Joo ^a   Park, Chansung ^a   Kwon, Youngmee ^a   Kim, Eun A ^a   Ko, Kyoung Lan ^a   Park, In Hae ^a   Lee, Keun Seok ^a   Shin, Kyung Hwan ^a   Lee, Seeyoun ^a   Kim, Seok Won ^a   Kang, Han Sung ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; TAMOXIFEN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT; TAXOID;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CANCER STAGING; MALE; MIDDLE AGED; PROGNOSIS; SCINTISCANNING; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74649084527     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0710-3     Document Type: Article

References (24)

1. B Fisher A Brown E Mamounas, et al. 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483 2493 1:CAS:528:DyaK2sXkslymsr8%3D 9215816
2. AC Wolff NE Davidson 2000 Primary systemic therapy in operable breast cancer J Clin Oncol 18 1558 1569 1:STN:280:DC%2BD3c3gtVGisg%3D%3D 10735905
3. P Rastogi SJ Anderson HD Bear, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
4. MR Machiavelli AO Romero JE Perez, et al. 1998 Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma Cancer J Sci Am 4 125 131 1:STN:280:DyaK1c7ptlGrsA%3D%3D 9554929
5. SM Scholl A Fourquet B Asselain, et al. 1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 Eur J Cancer 30A 645 652 10.1016/0959-8049(94)90537-1 1:STN:280:DyaK2czmtFyltw%3D%3D 8080680 (Pubitemid 24164252)
6. B Fisher J Bryant N Wolmark, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 1:CAS:528:DyaK1cXlsFCgurg%3D 9704717
7. HM Kuerer LA Newman TL Smith, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 1:CAS:528:DyaK1MXht1Wmur4%3D 10080586
8. AU Buzdar NK Ibrahim D Francis, et al. 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 10.1200/JCO.2005.07.032 1:CAS:528:DC%2BD2MXlslWntr8%3D 15738535 (Pubitemid 46252462)
9. AM Gonzalez-Angulo SE McGuire TA Buchholz, et al. 2005 Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy J Clin Oncol 23 7098 7104 10.1200/JCO.2005.11.124 16192593 (Pubitemid 46264016)
10. LG Estevez WJ Gradishar 2004 Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer Clin Cancer Res 10 3249 3261 10.1158/1078-0432.CCR-03-0133 1:CAS:528:DC%2BD2cXkt1Ghsrc%3D 15161677 (Pubitemid 38685428)
11. KS Lee J Ro BH Nam, et al. 2008 A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer Breast Cancer Res Treat 109 481 489 10.1007/s10549-007-9672-y 1:CAS:528:DC%2BD1cXlvVCgtro%3D 17653851 (Pubitemid 351692059)
12. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
13. RL Wahl K Zasadny M Helvie, et al. 1993 Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 2101 2111 1:STN:280:DyaK2c%2FksFyisQ%3D%3D 8229124
14. LP Adler JP Crowe NK al-Kaisi JL Sunshine 1993 Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-d-glucose PET Radiology 187 743 750 1:STN:280:DyaK3s3mvV2jsg%3D%3D 8497624
15. OE Nieweg EE Kim WH Wong, et al. 1993 Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer Cancer 71 3920 3925 10.1002/1097-0142(19930615)71:12<3920::AID-CNCR2820711220>3.0. CO;2-N 1:STN:280:DyaK3s3osVGjtw%3D%3D 8389655
16. IC Smith AE Welch AW Hutcheon, et al. 2000 Positron emission tomography using [(18)F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 1676 1688 1:STN:280: DC%2BD3c3islyjsg%3D%3D 10764428
17. M Schelling N Avril J Nahrig, et al. 2000 Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689 1695 1:STN:280:DC%2BD3c3islyjsw%3D%3D 10764429
18. DC Abraham RC Jones SE Jones, et al. 1996 Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging Cancer 78 91 100 10.1002/(SICI)1097-0142(19960701)78:1<91:: AID-CNCR14>3.0.CO;2-2 1:STN:280:DyaK283ms12huw%3D%3D 8646731 (Pubitemid 26189909)
19. SJ Vinnicombe AD MacVicar RL Guy, et al. 1996 Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation Radiology 198 333 340 1:STN:280:DyaK287kvVOktQ%3D%3D 8596827
20. P Chollet S Charrier E Brain, et al. 1997 Clinical and pathological response to primary chemotherapy in operable breast cancer Eur J Cancer 33 862 866 10.1016/S0959-8049(97)00038-5 1:CAS:528:DyaK2sXks1Srt7Y%3D 9291806 (Pubitemid 27287036)
21. H Kaida M Ishibashi T Fujii, et al. 2008 Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device Ann Nucl Med 22 95 101 10.1007/s12149-007-0092-1 18311533 (Pubitemid 351328970)
22. Duch J, Fuster D, Munoz M, et al. (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. [Epub ahead of print].
23. 18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy Ann Oncol 15 1352 1357 10.1093/annonc/mdh345 15319241 (Pubitemid 39295023)
24. 18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology Ann Oncol 19 1573 1577 10.1093/annonc/mdn185 1:STN:280:DC%2BD1crjtVeksg%3D%3D 18552360